An interventional study of Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device and Cataract surgery in Primary Open Angle Glaucoma, sponsored by Nova Eye, Inc.. Recruiting at 4 sites in 2 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2025-04-18.
Sponsored by Nova Eye, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Glaucoma, Open-Angle with a site in Germany — 7 open to participants now, 11 under way, none of them phase 3. Glaucoma, Open-Angle · Germany.
Among the 64 studies in Glaucoma, Open-Angle with a site in Germany, this one is the 22nd largest by planned enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2022, is one of 22 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 57th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →7 of the 64 studies in Glaucoma, Open-Angle with a site in Germany are open now. Recruiting first, the newest first:
Santen SAS · Sites in Germany, Austria, Belgium and 5 more countries
Ages 18–85
Okuvision GmbH · Sites in Germany
Ages 40+
Elios Vision, Inc. · Sites in Germany, Belgium, France and 3 more countries
Ages 40+
Wuerzburg University Hospital · Sites in Germany
Ages 18+
Nova Eye, Inc. · Sites in Germany, Spain, United Kingdom
Ages 22+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 9 · Phase 4 9
First in 1997; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is close to the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 60 across the 46 interventional studies, 246 across the 18 observational. Of the 47 that completed or were terminated, 20 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 64 have an industry lead sponsor. The 10 most frequent:
Nova Eye, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Nova Eye, Inc. has 3 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
5 of the studies in Glaucoma, Open-Angle with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT04524416iSTAR MedicalMINIject Global Long-Term Follow-up Study | 2026-12 |
| NCT05786196Nova Eye, Inc.Multicenter Glaucoma Study Investigating Standalone Canaloplasty | 2026-12 |
| NCT05564091Nova Eye, Inc.Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma | 2027-06 |
| NCT07235592Santen SASPRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 64 studies in Glaucoma, Open-Angle with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, multicenter, randomized, single-masked, post-market clinical trial comparing cataract surgery in conjunction with ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.) to cataract surgery only in patients with mild to moderate, primary open angle glaucoma. Subjects will be followed for 24 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following prior treatments for glaucoma (study eye):
Ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.)
Device: Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device
Cataract surgery alone
Procedure: Cataract surgery
360 degree microcatheterization and viscodilation of Schlemm's canal
Cataract surgery alone
Also known as: Phacoemulsification
Reduction in mean Intraocular Pressure (IOP) at 12 months compared to baseline
IOP will be measured at each study visit using Goldmann applanation tonometry
Time frame: 12 months
Reduction in number of glaucoma medications at 12 months compared to baseline
The number of glaucoma medications will be recorded at 12 months compared to baseline
Time frame: 12 months
Reduction in mean Intraocular Pressure (IOP) at 24-months compared to baseline
IOP will be measured at each study visit using Goldmann applanation tonometry
Time frame: 24 months
Reduction in glaucoma medications at 24-months compared to baseline
The number of glaucoma medications will be recorded at 24-months compared to baseline
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Jun 2027, 57 months after the start.
Of 70 industry-sponsored interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 57 months is above that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.